ESD for Colorectal LSL Using a Selective Strategy - a Prospective Cohort Study

NARECRUITING

Colonic Laterally spreading lesions (LSL) =\> 20mm are at high risk to progress to cancer. Overt stigmata of submucosal invasive cancer (SMIC) has been well characterized and includes ulceration and surface pit pattern changes as per the Kudo classification of type V. In a recent report, risk factors for LSL with SMIC and no overt stigmata (i.

e. covert SMIC) were described. Resection of these lesions 'en-bloc' can allow for better histological staging and potentially reduce the need for surgical resection.

Study details:

With over 14,000 patients diagnosed annually, colorectal carcinoma (CRC) is the second most frequently invasive malignancy in Australia. By not only diagnosing CRC at an early stage, but also removing precursor adenomas, colonoscopy with polypectomy reduces the risk of developing and dying from CRC. Laterally spreading lesions \>= 20mm (LSL) are more likely to progress to cancer.

The prevalence of LSL ranges from 1-5% in screening population. The risk of malignant progression of colorectal adenomas found during colonoscopy increases with lesion size, i. e.

the cancer preventive effect is likely to be maximal in large lesions. Patients with LSL have a higher risk of malignancy and a higher recurrence rate of adenoma after lesion removal compared with diminutive polyps. Endoscopic imaging can now accurately predict LSL with submucosal invasive cancer (SMIC) through assessment of LSLs morphology (Paris classification, granularity) and surface pit-pattern (Kudo classification).

Such cases can be considered to have LSL with overt risk of SMIC. Recent publication has highlighted that some LSLs might hrbor SMIC without overt morphological features (i. e.

high risk for covert SMIC). These LSL with high risk of covert SMIC stratified LSLs based on lesion location and lesion morphology. Generally LSLs can be safely and effectively removed by wide field endoscopic mucosal resection (WF-EMR) in over 90% of cases in competent hands.

One of the draw backs with WF-EMR is it requires piecemeal resection and thus is limited in providing assessment of complete excision and depth of submucosal invasion in cases where SMIC is present. Thus, endoscopic en-bloc resection is preferable from an oncologic standpoint to obtain a single specimen for proper histopathologic assessment. Endoscopic submucosal dissection (ESD) is a technique that is now becoming the preferred method for achieving a complete endoscopic and histologic resection, referred to as R0.

Evidence from retrospective cohort and meta-analyses suggests ESD provides a more consistent oncologic resection with a reduced rate of recurrence. However, the major limitations with the technique relate to increased procedure time and the skill-set required for performing the procedure. One of the other major limitations of ESD is significant cost associated with the procedure, which includes procedure time and additional equipment in addition to the treatment of any subsequent complications.

As such the implementation of ESD as the standard of care for all colorectal lesions has not been undertaken in Western countries, however it may have an important role for selective cases especially where there is concern for sub-mucosal invasive cancer (SMIC). The investigators propose a selective ESD strategy to be performed for patients focusing on overt evidence of SMIC and those at high risk of covert SMIC (defined as risk \>10%). The investigators will follow a prospective cohort study assessing the use of selective ESD strategy in the colorectum in the Western population.

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  1. All patients referred for colorectal resection of large laterally spreading lesions in colon.
  2. Can give informed consent to trial participation

Exclusion criteria

  1. Previous resection or attempted resection of target adenoma lesion
  2. Endoscopic appearance of invasive malignancy
  3. Age less than 18 years
  4. Pregnancy
  5. Active Inflammatory colonic conditions (e.g. inflammatory bowel disease)
  6. Use of anticoagulant or antiplatelet agents other than aspirin outside of internationally recognised guidelines
  7. American Society of Anesthesiology (ASA) Grade IV-V

Eligibility

Age eligible for study : NA

Healthy volunteers accepted : No

Gender eligible for study: ALL

Things to know

Study dates

Study start:

Primary completion:

Study completion finish:

study type

Study type

TREATMENT

phase

Phase

    NA

trial

Study ID

NCT04008407

Intervention or treatment

PROCEDURE: Endoscopic Submucosal Dissection

PROCEDURE: Endoscopic Mucosal Resection

Conditions

  • Colorectal Neoplasm
  • Endoscopic Mucosal Resection
  • Condition: Colorectal Neoplasm, Endoscopic Mucosal Resection

  • PROCEDURE: Endoscopic Submucosal Dissection and other drugs

  • Westmead, New South Wales, Australia

  • Sponsor: Western Sydney Local Health District

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial?

If you're a clinic or sponsor, you can claim this study

Research sites nearby

Closest Location:

Westmead Endoscopy Unit

Select from list below to view details:

  • Westmead Endoscopy Unit

    Westmead, New South Wales, Australia

Loading map...

Who is running the clinical trial?

WSLHD

Western Sydney Local Health District

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/ArmIntervention/Treatment
ACTIVE_COMPARATOR: ESD
  • Lesion with overt stigmata of SMIC or those with high risk (=\> 10%) for covert SMIC.
Procedure: Endoscopic Submucosal Dissection
    ACTIVE_COMPARATOR: EMR
    • Lesion with no overt or a low risk for (\<10%) for covert SMIC
    Procedure: Endoscopic Mucosal Resection

      What is the study measuring?

      Primary Outcome

      MeasureDescriptionTime Frame
      Rate of surgical referralIncidence of surgical referral due to non-curative endoscopic resection.3 months post procedure

      Secondary Outcome

      MeasureDescriptionTime Frame
      R0 resection rateRate of en-bloc resection with clear resection margins.3 months post procedure
      En Bloc resection rateRate of en-bloc resection3 months post procedure
      Technical success rateRate of procedures completed as per protocol3 months post procedure
      Duration of procedureProcedure duration in minutes.procedure
      Adenoma recurrence rateRate of recurrent adenoma at resection site on follow-up.3 years post procedure
      Are you running this trial?If you're a clinic or sponsor, you can claim this study.

      References

      Clinical Trials Gov: ESD for Colorectal LSL Using a Selective Strategy - a Prospective Cohort Study

      Other trials to consider

      Loading suggested trials...

      Top searched conditions